Vir Biotechnology, Inc. (VIR)
10.71
+0.80
(+8.07%)
USD |
NASDAQ |
Aug 25, 16:00
10.90
+0.19
(+1.77%)
After-Hours: 05:34
Vir Biotechnology Enterprise Value : 1.371B for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 1.371B |
| August 24, 2026 | 1.235B |
| August 21, 2026 | 1.213B |
| August 20, 2026 | 1.117B |
| August 19, 2026 | 1.212B |
| August 18, 2026 | 1.164B |
| August 17, 2026 | 1.147B |
| August 14, 2026 | 1.122B |
| August 13, 2026 | 1.081B |
| August 12, 2026 | 1.075B |
| August 11, 2026 | 1.069B |
| August 10, 2026 | 1.063B |
| August 07, 2026 | 1.051B |
| August 06, 2026 | 1.042B |
| August 05, 2026 | 1.100B |
| August 04, 2026 | 1.110B |
| August 03, 2026 | 1.064B |
| July 31, 2026 | 1.024B |
| July 30, 2026 | 1.064B |
| July 29, 2026 | 1.020B |
| July 28, 2026 | 1.056B |
| July 27, 2026 | 1.047B |
| July 24, 2026 | 1.029B |
| July 23, 2026 | 1.139B |
| July 22, 2026 | 1.141B |
| Date | Value |
|---|---|
| July 21, 2026 | 1.152B |
| July 20, 2026 | 1.120B |
| July 17, 2026 | 1.154B |
| July 16, 2026 | 1.149B |
| July 15, 2026 | 1.184B |
| July 14, 2026 | 1.164B |
| July 13, 2026 | 1.203B |
| July 10, 2026 | 1.244B |
| July 09, 2026 | 1.308B |
| July 08, 2026 | 1.323B |
| July 07, 2026 | 1.293B |
| July 06, 2026 | 1.254B |
| July 02, 2026 | 1.257B |
| July 01, 2026 | 1.176B |
| June 30, 2026 | 1.283B |
| June 29, 2026 | 1.291B |
| June 26, 2026 | 1.235B |
| June 25, 2026 | 1.210B |
| June 24, 2026 | 1.222B |
| June 23, 2026 | 1.255B |
| June 22, 2026 | 1.160B |
| June 18, 2026 | 1.094B |
| June 17, 2026 | 1.117B |
| June 16, 2026 | 1.006B |
| June 15, 2026 | 1.006B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Caribou Biosciences, Inc. | 100.89M |
| Arrowhead Pharmaceuticals, Inc. | 12.32B |
| Oncolytics Biotech, Inc. | 103.70M |
| Sangamo Therapeutics, Inc. | 53.43M |
| Sarepta Therapeutics, Inc. | 2.256B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 80.08M |
| Revenue (Quarterly) | 238.95M |
| Total Expenses (Quarterly) | 158.87M |
| EPS Diluted (Quarterly) | 0.4742 |
| Gross Profit Margin (Quarterly) | 98.83% |
| Profit Margin (Quarterly) | 33.51% |
| Earnings Yield | -17.38% |
| Normalized Earnings Yield | -17.22 |